




PHARMACEUTICAL 2017

Ayala Pharmaceuticals Inc.
Rank 122 of 292

ADVAXIS
IMMUNOTHERAPIES™





RealRate

PHARMACEUTICAL 2017

Ayala Pharmaceuticals Inc. Rank 122 of 292

ADVAXIS
IMMUNOTHERAPIES™

The relative strengths and weaknesses of Ayala Pharmaceuticals Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Ayala Pharmaceuticals Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 99% points. The greatest weakness of Ayala Pharmaceuticals Inc. is the variable Other Liabilities, reducing the Economic Capital Ratio by 19% points.

The company's Economic Capital Ratio, given in the ranking table, is 120%, being 117% points above the market average of 2.9%.

Input Variable	Value in 1000 USD
Assets, Current	159,875
Cost of Goods Sold	0
Intangible Assets	4,329
Liabilities, Current	27,706
Liabilities, Non-Current	0
Other Assets	451
Other Compr. Net Income	0
Other Expenses	-2,536
Other Liabilities	22,035
Other Net Income	400
Other Revenues	3,995
Property and Equipment	4,389
Research and Development	48,775
Selling, General and Administrative Expense	31,713

Output Variable	Value in 1000 USD
Assets	169,044
Liabilities	49,742
Expenses	77,951
Revenues	3,995
Stockholders Equity	119,302
Net Income	-73,556
Comprehensive Net Income	-73,556
Economic Capital Ratio	120%